Zoliflodacin Effective Against Gonorrhea in Chlamydia Co-infected Patients

New data presented at IDWeek 2026 shows that zoliflodacin, an FDA-approved oral antibiotic for uncomplicated urogenital gonorrhea, maintains high cure rates even when patients are co-infected with Chlamydia trachomatis. This indicates the drug's efficacy against gonorrhea is not compromised by chlamydia, though separate testing and treatment for chlamydia remain necessary.